European Journal of Cancer Q1 Unclaimed

Elsevier Ltd. United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

European Journal of Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 205. Journal with a Single blind Peer Review review system, and It has a price of 2655 €. The scope of the journal is focused on Cancer, Oncology, Clinical Oncology, Medicine. It has an SJR impact factor of 3,41 and it has a best quartile of Q1. It is published in English.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

2655 €

Gold OA

-

Green OA

- €

Non OA

Metrics

European Journal of Cancer

3,41

SJR Impact factor

205

H Index

352

Total Docs (Last Year)

1203

Total Docs (3 years)

10343

Total Refs

7616

Total Cites (3 years)

1012

Citable Docs (3 years)

7,41

Cites/Doc (2 years)

29,38

Ref/Doc

Aims and Scope


Cancer Oncology Clinical Oncology Medicine


Best articles

(111Indium-DTPA-D-Phe) octreotide scintigraphy in the diagnostic assessment of palpable breast lumps

View more

13-Cis-retinoic acid and alphainterferon in advanced squamous cell cancer of the oesophagus

View more

163 O - Aortic infuslon (ADM, MMC, CDDP) and stop-flow (MMC, ADM) for systemically pretreated and progresslve FLGO III c and IV ovarian cancer-45 patients

View more

26 P - Monitoring of neurotoxicity of taxanes

View more

47 P - The role of basic fibroblast growth factor (bFGF) in human non small cell lung cancer (NSCLC)

View more

74 O - Selective anti-leukemic potential of HLA-incompatible bone marrow transplants

View more

A Glimpse of the Future. New Directions in the Treatment of Colorectal Cancer

View more

A high pretreatment serum level of VEGF is associated with poor outcome in small cell lung cancer

View more

A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the Combined Hormonal Agent Trialists Group (CHAT)

View more

A novel herpes vector for the high efficiency transduction of primary hematopoietic cells

View more

A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma

View more

A phase III randomised study of carboplatin and amifostine (A) vs carboplatin and G-CSF in patients with inoperable non small cell lung cancer (NSCLC)

View more
SHOW MORE ARTICLES

A pure antiestrogen, IC1182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in female nude mice

View more

Accumulation of p53 is associated with response to pre-operative chemotherapy in primary operable breast cancer

View more

Active surveillance' for stage I testis cancer

View more

Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2

View more

All-trans retinoic acid enhances gap junctional intercellular communication among renal epithelial cells in vitro treated with renal carcinogens

View more

Apoptosis of Ovarian carcinoma cells (N1) by TNF and it's possible targets

View more

B.I.G. - brother is watching you?

View more

B.I.G. - is beautiful

View more

Bile duct stents: Is there an increased rate of complications in patients receiving chemotherapy?

View more

Breast conservation in the 21st century

View more

Cancer information: a cost-effective intervention

View more

Cancer prevention in the year 2025

View more

Comments

No comments ... Be the first to comment!